“Was it FDA approved?”
No. FDA says compounded drugs are not FDA-approved, and a PCAC vote is not a drug-approval action.
Field Guide 04 · reviewed July 25, 2026
An advisory “yes” is not FDA approval.
The July peptide votes matter. They still answer a narrower question than the headlines, product pages, and social posts often claim.
TL;DR
PCAC advised FDA to include both forms of six peptide groups on the 503A Bulks List and advised against both emideltide forms. The recommendations are non-binding. FDA has not made its final determinations, approved these substances as drugs, or verified products sold under their names.
What happened on July 23–24
FDA asked fourteen separate questions: free base and acetate for seven peptide groups. BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax received recommendations for inclusion in both forms. Emideltide received recommendations against inclusion in both forms. Open all fourteen tallies →
Stage 1 · completeFDA staff analysis
Agency staff published chemistry, evidence, safety, and compounding-policy reviews and recommended against all seven groups.
Stage 2 · completePCAC advice
The advisory committee recorded fourteen non-binding votes and reached a different recommendation for six groups.
Stage 3 · pendingFinal FDA action
FDA considers the committee input and completes its own review. The advisory vote does not perform this step.
Separate questionThe actual product
List status cannot establish the identity, concentration, sterility, quality, labeling, or clinical performance of a particular vial.
Why the 503A Bulks List matters
FDA explains that state-licensed physicians and pharmacists compounding under section 503A may use a bulk drug substance only through specified pathways. One pathway is appearance on the 503A Bulks List when an applicable USP or NF monograph does not exist and the substance is not a component of an FDA-approved drug product. The committee advises FDA as the agency evaluates nominated substances; the committee does not write the final list by voting.
The four questions readers are really asking
“Can anyone compound it now?”
The committee vote alone does not create final list placement or establish that a particular compounding activity satisfies every applicable condition.
“Did the evidence improve?”
No new clinical participants appeared because a vote occurred. The staff record, advisory recommendation, and clinical evidence remain separate records.
“Does this validate an online vial?”
No. A regulatory recommendation cannot authenticate an unidentified product or establish its strength, sterility, purity, storage history, or manufacturer.
What PepCurrent watches next
Written meeting minutes can add an easier-to-search official record. A later FDA action can change final list status. Neither should be silently folded into the committee stage: PepCurrent will date the new source, identify the stage that changed, preserve the prior record, and update the affected status files separately.
Official receipts
FDA — Exact July 2026 PCAC voting questionsOfficial PDF ↗ FDA — Pharmacy Compounding Advisory Committee purposeOfficial page ↗ FDA — Bulk drug substances under section 503AOfficial page ↗ FDA — Understanding the risks of compounded drugsOfficial page ↗Boundary: This guide explains public FDA records. It is not medical advice, a legal opinion on a particular compounding activity, a treatment recommendation, or an evaluation of an individual product.